ESTRO 2020 Abstract book

S648 ESTRO 2020

also found that hemodynamically patients remained stable with minimum side effects in the dexmedetomidine group. Dexmedetomidine also provided better sedation resulting in better patient satisfaction for the peri-operative period. Conclusion The present study suggests that 10 μg dexmedetomidine with bupivacaine by intrathecal route is better analgesic adjuvant than 25 μg fentanyl with bupivacaine in patients undergoing intracavitary brachytherapy under spinal anaesthesia. It provides hemodynamically stable conditions, minimal side effects, significantly prolong the duration of sensory block and good quality and duration of peri-operative analgesia. PO-1140 Role of Functional Imaging in evaluation of Radiation Colitis A. Jajodia 1 , A. Chaturvedi 1 , N. Gupta 2 , A. Rao 1 , M. Gairola 3 , S. Mitra 3 , V. Mahawar 1 , P. Ahlawat 3 , S. Goyal 4 , V.P.B. Koyyala 4 , S. Aggarwal 3 , S. Tandon 3 , R. Tripathi 5 , S. Pasricha 6 , A. Mehta 7 1 Rajiv Gandhi Cancer Institute And Research Centre, Radiology, New Delhi, India ; 2 Rajiv Gandhi Cancer Institute and Research Centre, Gastroenterology, New delhi, India ; 3 Rajiv Gandhi Cancer Institute and Research Centre, Radiation Oncology, New Delhi, India ; 4 Rajiv Gandhi Cancer Institute and Research Centre, Medical Oncology, New Delhi, India ; 5 Rajiv Gandhi Cancer Institute and Research Centre, Research, New delhi, India ; 6 Rajiv Gandhi Cancer Institute and Research Centre, Oncopathology, New delhi, India ; 7 Rajiv Gandhi Cancer Institute and Research Centre, Molecular Diagnosis, New delhi, India Purpose or Objective Despite major revisions in conventional radiotherapy techniques , Radiation induced colitis (RIC) is encountered as a pestering problem .The purpose of our study was to compare quantitative MRI and histopathological (HPE) features in patients with genitourinary and anal canal cancer. Material and Methods MR study was retrospectively analyzed in patients presenting ( n= 62) to Gastroenterology department of our institute with symptoms attributed to RIC. Sigmoidoscopy findings suggestive of RIC were taken into account and MRI quantitative analysis was done in finally 48 patients . Evaluated parameters included T1 ratio ( T1 post contrast/T1 pre-contrast), T2 M-S ratio (T2 mural wall/ striated muscle) ; T2 M-M (T2 mural wall/mesentery ) , T2 M-CSF (T2 mural wall/CSF ) and apparent diffusion coefficient (ADC). The MR examination was within 2 weeks prior to Sigmoidoscopy . Hematological assessment of total leukocyte count and polymorphs was done. These were compared with final HPE using Chi-squared tests. HPE confirmation of RIC was available in 18 patients. Results Forty eight patients (mean age 56.25 years, 13 male) with mean dose (74 Gy) were included. T1 ratio, T2 M-S ratio, T2 M-M , T2 M-CSF and apparent diffusion coefficient (ADC) ratio correlated with HPE as follows (p = 0.02, 0.823, 0.332, 0.412, 0.709 respectively). HPE correlation with TLC had a p value of 0.823. Conclusion Quantitative MRI characteristic like T1 ratio is potential marker of the histopathological inflammation in RIC. PO-1141 Prognostic factors in gynaecological cancer patients treated with radiotherapy for brain metastases E. Nakken 1 , S.S. Os 1 , K. Skipar 1 , K. Bruheim 1 1 Oslo University Hospital, Radiumhospitalet, Oslo, Norway

Brain metastases (BM) from gynaecological cancers are rare and carry a poor prognosis. No common treatment guidelines exist for this patient group due to lack of data. For clinicians, life prognostication and treatment decision is a difficult task in this situation. Information that can shed light over this issue is therefore much needed. Material and Methods A retrospective analysis of patients with BM from a gynaecological cancer treated at the Norwegian Radium Hospital, Oslo University Hospital was performed. All patients receiving radiotherapy due to BM from 2006-2017 were identified from the hospitals radiotherapy registry. Medical data were found in the hospital’s medical records. Both patients treated with stereotactic brain radiotherapy (SBRT) and whole brain radiotherapy (WBRT) were included. Results 117 patients were eligible for analysis. Mean age at diagnosis of BM was 63 years (range 24-91). Mean time from primary diagnosis to diagnosis of BM was 48 months. 36 patients (31 %) had a single metastasis, 30 % had 2-4 metastases and the remaining 39 % was diagnosed with more than 4 metastases. 67 % of the patients received WBRT only, 14 % received SBRT while the rest (20 %) had a combination of WBRT and SBRT. Surgery was performed in addition to radiotherapy in 13 % of the patients. Median overall survival (OS) from diagnosis of brain metastases to death was 5.2 months (range 0.03 – 136.1). 29 patients (25 %) were still alive 12 months after treatment. The majority of patients had a primary diagnosis of ovarian cancer (44%). Endometrial, cervical and vulvar cancer accounted for 33 %, 21 % and 3 % respectively. 18 patients (15%) did not show any sign of extracranial disease. 43 patients (37 %) had an ECOG score of 3-4 at the time of diagnosis of BM. Absence of extracranial disease and low ECOG status (0-2) was significantly associated with longer survival (figure 1 and 2). Neither primary gynaecological cancer diagnosis, age at diagnosis of BM, time from primary diagnosis to BM diagnosis or number of BM was associated with survival. For patients surviving more than 12 months only absence of extracranial disease showed a significant correlation. 22 % of the patients received radiotherapy within the last 30 days of their life

Purpose or Objective